---
layout: default
title: Gallium
parent: 僅模型預測 (L5)
nav_order: 202
evidence_level: L5
indication_count: 0
---

# Gallium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Gallium: Insufficient Data for Full Repurposing Evaluation

## One-Sentence Summary

Gallium is a metallic element whose pharmaceutical compounds (e.g., gallium nitrate) have historically been investigated in oncology and infectious disease contexts.
However, this Evidence Pack contains **no TxGNN predicted indications**, **no regulatory registrations in Denmark**, and **no safety data** — making a complete repurposing evaluation impossible at this stage.
A full data remediation pass is required before this candidate can be assessed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No data available |
| Predicted New Indication | No prediction data available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction data absent — no supporting studies retrievable) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No mechanism of action data is available in this Evidence Pack. A DrugBank query was logged (query ID 2, status: `success`, result count: 1), but no MOA field was populated from it. This is a critical gap because the entire mechanistic rationale for any repurposing hypothesis depends on understanding how gallium compounds exert their biological effects.

Based on general pharmacological knowledge, gallium compounds (such as gallium nitrate) are known to interfere with iron metabolism — gallium(III) mimics iron(III) and disrupts iron-dependent cellular processes. This has been the basis for its investigation in hypercalcemia of malignancy (via inhibition of bone resorption) and in antimicrobial and antitumour contexts. However, **none of this is confirmed by the data in this Evidence Pack**, and no predicted indication from TxGNN is present to evaluate.

Because the `predicted_indications` array is empty, it is not possible to assess whether any mechanistic bridge exists between a known indication and a candidate new one. No report section on clinical trials or literature can be generated from this dataset.

---

## Denmark Market Information

No marketing authorisations are registered for Gallium with the Danish Medicines Agency (Lægemiddelstyrelsen). The drug is not currently available on the Danish market in any formulation.

> Note: Gallium nitrate (Ganite®) holds approval in the United States for hypercalcemia of malignancy, but no equivalent EU/EMA or national Danish authorisation was identified in this dataset.

---

## Safety Considerations

No safety data is available in this Evidence Pack. All fields under `key_warnings` and `contraindications` are flagged as data gaps, and the drug–drug interaction (DDI) query returned no results.

> Please refer to the approved Summary of Product Characteristics (SmPC) or equivalent regulatory documents for safety information before any clinical use is considered.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Gallium is non-actionable in its current state — the predicted indications array is empty, no regulatory authorisation exists in Denmark, and all safety fields are missing. There is no TxGNN output to evaluate, and no evidence base (clinical trials or literature) was linked to any indication.

**To proceed, the following is needed:**

1. **Re-run TxGNN pipeline** for Gallium — confirm the correct DrugBank ID and verify that predicted indications are being generated and stored correctly. The DrugBank query returned 1 result but no DrugBank ID was populated in the `drug.drugbank_id` field; this mapping error likely caused the prediction pipeline to fail.
2. **Resolve MOA data gap (DG002)** — retrieve full mechanism of action from DrugBank API using the correct DrugBank compound ID.
3. **Retrieve safety data (DG001)** — obtain warnings and contraindications from the relevant SmPC or equivalent source; for EU use, check the EMA product database.
4. **Confirm drug identity** — "GALLIUM" is ambiguous (element vs. specific salt such as gallium nitrate, gallium maltolate, gallium citrate). The candidate ID should specify the exact compound and salt form before any evaluation can proceed.
5. **Check EMA/national authorisation databases** — confirm whether any gallium compound holds a centralised or mutual recognition authorisation valid in Denmark.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

